For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.
Beckman Coulter Access CEA Reagent, 100 determinations, 2 x 50 tests
Easily reorder reagents and American-made parts.
Enjoy the fair price promise.
Take pressure off your budget (and yourself)
Product Code: 33200
Manufacturer: Beckman Coulter
Shipping Weight: 10.00lbs (4.54kg)
Specifications
Brand: Access®
Manufacturer: Beckman Coulter
Country of Origin: France
Application: Reagent
For Use With: For use with Access Immunoassay Systems
Number of Tests: 2 X 50 Tests
Test Name: Carcinoembryonic Antigen
Test Type: Tumor Marker Assay
Intended Use
The Access CEA assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of Carcinoembryonic Antigen (CEA) levels in human serum, using the Access Immunoassay Systems. CEA measured by the Access Immunoassay Systems is used as an aid in the management of cancer patients in whom changing CEA concentrations have been observed.
Summary and Explanation
Carcinoembryonic antigen (CEA), first described by Gold and Freedman in 1965, was isolated from extracts of liver metastases of colon adenocarcinomas and normal fetal digestive tract. It is considered one of the most extensively investigated human tumor associated antigens. An immunologically heterogenous group of glycoproteins, CEA is Instructions For Use A33769 U English Access CEA MAY 2020 Page 1 of 12 approximately 200,000 daltons with 50-85% carbohydrates by weight. CEA is a member of the immunoglobulin superfamily and appears to have functions of an intercellular adhesion molecule. In addition, molecules structurally related to CEA (i.e. NCA, NCA-2, NFA) have been reported in normal adult tissues.
The measurement of serum CEA has shown substantial benefit in the prognosis and management of patients with malignant diseases, especially colorectal cancer. Serial measurements can be used to monitor patients for progression, regression or recurrence of cancer following treatment. A persistent elevation of CEA following therapeutic or surgical intervention signals residual disease or recurrence, whereas decreasing levels to within the normal range is indicative of successful intervention.
CEA is also elevated in the serum of patients with non-malignant diseases and in heavy smokers, therefore CEA should not be used in the diagnosis of cancer or for screening asymptomatic patients.
